Head-To-Head Contrast: Aditxt (NASDAQ:ADTX) versus ImmuCell (NASDAQ:ICCC)

ImmuCell (NASDAQ:ICCC) and Aditxt (NASDAQ:ADTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Institutional & Insider Ownership

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for ImmuCell and Aditxt, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0	1	0	0	2.00
Aditxt	1	0	0	0	1.00

Profitability

This table compares ImmuCell and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Aditxt	-360,152.50%	-374.60%	-105.93%

Valuation and Earnings

This table compares ImmuCell and Aditxt”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64 million	3.37	-$1.04 million	$0.08	128.12
Aditxt	$14,336.00	0.02	-$41.71 million	($100,788.35)	-0.00

ImmuCell has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Summary

ImmuCell beats Aditxt on 10 of the 12 factors compared between the two stocks.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.